Processa Pharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$1.01 | -$1.01 | -$1.01 |
| Q2 2024 | 1 | -$1.00 | -$1.00 | -$1.00 |
| Q3 2024 | 1 | -$0.76 | -$0.76 | -$0.76 |
| Q1 2025 | 1 | -$0.66 | -$0.66 | -$0.66 |
| Q2 2025 | 1 | -$0.55 | -$0.55 | -$0.55 |
| Q3 2025 | 1 | -$0.47 | -$0.47 | -$0.47 |
| Q4 2025 | 1 | -$0.48 | -$0.48 | -$0.48 |
Processa Pharmaceuticals, Inc. Earnings Date And Information
Processa Pharmaceuticals, Inc. last posted its earnings results on Wednesday, October 30th, 2024. The company reported $-1.03 earnings per share for the quarter, missing analysts' consensus estimates of $-1 by $0.03. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Processa Pharmaceuticals, Inc. has generated $-8 earnings per share over the last year ($-8.48 diluted earnings per share) and currently has a price-to-earnings ratio of -0.31. Processa Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 27th, 2025 based on prior year's report dates.
Processa Pharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 10/30/2024 | Q3 2024 | -$1.00 | -$1.03 | -0.03 | $0 | $0 |
| 08/13/2024 | Q2 2024 | -$0.98 | -$1.01 | -0.03 | $0 | $0 |
| 05/10/2024 | Q1 2024 | -$1.18 | -$1.10 | 0.08 | $0 | |
| 03/29/2024 | Q4 2023 | -$1.60 | -$1.30 | 0.3 | $0 | |
| 11/13/2023 | Q3 2023 | -$0.10 | -$1.50 | -1.4 | $0 | |
| 08/10/2023 | Q2 2023 | -$1.90 | $0 | |||
| 05/15/2023 | Q1 2023 | -$5.60 | $0.15 | 5.75 | $0 | |
| 03/30/2023 | Q4 2022 | -$5.00 | -$41.80 | -36.8 | $0 | |
| 11/08/2022 | Q3 2022 | -$6.80 | -$7.40 | -0.6 | $0 | |
| 08/11/2022 | Q2 2022 | -$6.40 | $0 | |||
| 05/12/2022 | Q1 2022 | -$4.80 | -$4.00 | 0.8 | $0 | |
| 03/30/2022 | Q4 2021 | -$3.60 | -$4.00 | -0.4 | $175,398 | |
| 11/12/2021 | Q3 2021 | -$4.20 | -$3.80 | 0.4 | $0 | |
| 08/12/2021 | Q2 2021 | -$3.00 | -$4.00 | -1 | $0 | |
| 05/13/2021 | Q1 2021 | -$0.10 | -$2.80 | -2.7 | $0 | |
| 03/25/2021 | Q4 2020 | -$0.35 | -$13.80 | -13.45 | $-277,948 | |
| 11/12/2020 | Q3 2020 | -$0.16 | -$11.00 | -10.84 | $0 | |
| 08/05/2020 | Q2 2020 | -$2.60 | $0 | |||
| 05/15/2020 | Q1 2020 | -$3.20 | $0 | |||
| 03/06/2020 | Q4 2019 | -$2.80 | $0 |
Processa Pharmaceuticals, Inc. Earnings: Frequently Asked Questions
-
When is Processa Pharmaceuticals, Inc.'s earnings date?
Processa Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 27th, 2025 based off last year's report dates.
-
How can I listen to Processa Pharmaceuticals, Inc.'s earnings conference call?
The conference call for Processa Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
-
How can I read Processa Pharmaceuticals, Inc.'s conference call transcript?
The conference call transcript for Processa Pharmaceuticals, Inc.'s latest earnings report can be read online.
-
How much profit does Processa Pharmaceuticals, Inc. generate each year?
Processa Pharmaceuticals, Inc. (:PCSA) has a recorded net income of $0. Processa Pharmaceuticals, Inc. has generated $-8.48 earnings per share over the last four quarters.
-
What is Processa Pharmaceuticals, Inc.'s price-to-earnings ratio?
Processa Pharmaceuticals, Inc. (:PCSA) has a price-to-earnings ratio of -0.31 and price/earnings-to-growth ratio is 0.
